APAC companies underrepresented in $33 billion I-O market, report finds

A new report finds that drug companies in the APAC region are underrepresented in the global immuno-oncology development space.

Business intelligence company GlobalData values the global market for immuno-oncology treatments at $33 billion.

Companies in the APAC region are involved in the development of just 6.4% of PD1/PDL1 combination therapies, the report finds.

Currently, Japan is leading the APAC region, with Takeda and Eisai out front. However, China is on course to outperform Japan in the near future.